Beiersdorf
VC Fund
Hamburg, Germany
Beiersdorf is a VC fund in Hamburg focused on Biotechnology and Wellness. Beiersdorf AG is a German personal-care company based in Hamburg, manufacturing personal-care products and pressure-sensitive adhesives.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Beiersdorf invests in
Stages Beiersdorf invests in
Countries Beiersdorf invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2M–$23M
- Series A
- $4.4M–$10M
Investment Focus
Industry
- Biotechnology 4 (36%)
- Wellness 2 (18%)
- Health Care 2 (18%)
- Manufacturing 2 (18%)
- Apps 1 (9%)
Stage
- Series A 5 (45%)
- Seed 3 (27%)
- Pre-Seed 1 (9%)
- Venture - Series Unknown 1 (9%)
Country
- United States 3 (27%)
- United Kingdom 2 (18%)
- France 1 (9%)
- Sweden 1 (9%)
- Germany 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Felicitas Hackmann
Marketing Comms, Content Creation & Project Manager
|
Marketing Comms, Content Creation & Project Manager | Total investments: 0 | Find email | |
Michael Fuchs
Brand Manager 8x4
|
Brand Manager 8x4 | Total investments: 0 | Find email | |
Sara Al Madani
Brand Ambassador
|
Brand Ambassador | Total investments: 0 | Find email | |
| CEO | Total investments: 0 | Find email | ||
Ulrich Schmidt
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Melt&Marble
|
Melt&Marble, formerly known as Biopetrolia, was founded patent holding firm for co-founder Professor Jens Nielsen’s research group. | $8.5M / Series A / Dec 08, 2025 | |
Cellvie
|
Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.Mitochondria are at the heart of complex life's origin. Likely a bacterium at the time, the would-be-organelle merged with a simple organism, entering into a symbiotic relationship: The mitochondria began supplying theenergy for elaborate cellular functions to evolve, while the organism provided the mitochondria with an environment to thrive. Today, mitochondria are found in all human cells, except for red blood cells. They take on a pivotal role in cellular fate, as they produce most of the energy (ATP) and are involved in a large number of cellular and metabolic processes. The density of the organelles is particularly high in cells requiring a lot of cellular energy - e.g. cardiomyocytes or brain cells.Mitochondria function, and hence energy supply to the cell, may be impaired due to acute insults (e.g. ischemia) or genetic disorders (e.g. LOHN).Researchers at Harvard University developed an approach for mitochondria augmentation and replacement to ameliorate the damages from ischemia-reperfusion injury. Ischemia is a lack of blood flow leading to an undersupply of oxygen and an impairment of mitochondria function. Reperfusion describes the re-introduction of blood flow, inducing an oversupply of oxygen. Both, ischemia and reperfusion, damage cells, with the mitochondria dysfunction being at the heart of the injury. The cascade of events, from ischemia to reperfusion, will eventually lead to cell death. The most prominent acute conditions associated with ischemia-reperfusion injury are heart attacks. At Cellvie, we are developing a means to transplant viable mitochondria into the compromised cells, to interrupt the said cascade of events, re-enabling the cells to turn oxygen into energy via the mitochondria. | $5M / Seed / Sep 09, 2025 | |
ReVentas
|
ReVentas is dedicated to transforming how the world recycles plastics, aiming for a sustainable and circular economy. | Series A / May 26, 2025 | |
DePoly
|
DePoly is a chemical recycling company that converts post-consumer PET plastic and polyester textiles back into their main raw components at room temperature, without the need to pre-wash, pre-sort, or separate out other plastics. The raw material can then be sold back to the industry so that new virgin-quality plastic items can be made, creating atruly circular plastic economy. | $23M / Seed / Apr 29, 2025 | |
Vincere Biosciences
|
Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $5M / Series A / Apr 01, 2025 | |
DeepLife
|
DeepLife uses deep learning on multi-omics data to model cells and efficiently engineer their behavior.DeepLife is a biotech company with a mission to build the next generation of system biology. The company works in a highly collaborative translational manner, to facilitate the transition of discoveries from the laboratory to patients. Thecompany operates through collaboration with academic groups in their respective areas of expertise. | $10M / Series A / Dec 11, 2024 | |
|
DePoly
|
DePoly is a chemical recycling company that converts post-consumer PET plastic and polyester textiles back into their main raw components at room temperature, without the need to pre-wash, pre-sort, or separate out other plastics. The raw material can then be sold back to the industry so that new virgin-quality plastic items can be made, creating atruly circular plastic economy. | $13.8M / Seed / Jun 27, 2023 | |
Salvalco
|
Salvalco Eco-Valves are new aerosol valves specifically designed to enable aerosols to be propelled successfully by harmless gases such as Nitrogen, Carbon Dioxide or simply Compressed Air. | $3.1M / Venture - Series Unknown / May 16, 2022 | |
Dermanostic
|
Dermanostic is an e-health app where patients receive a medical diagnosis and therapy recommendation for skin diseases. | $2M / Seed / Jan 11, 2022 | |
Routinely
|
Routinely is an online store that sells skincare products. Their products include cleaners, moisturizers, and serums. They allow consumers to directly buy goods or services from a seller over the internet. Their products serve consumers. | Pre-Seed / May 20, 2020 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Beiersdorf invest in?
Beiersdorf invests primarily in Biotechnology, Wellness and Health Care startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Beiersdorf's check size?
Beiersdorf typically joins rounds of $2M–$23M at Seed and $4.4M–$10M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Beiersdorf participates in.
How do I contact Beiersdorf?
Public channels for Beiersdorf include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Beiersdorf?
The team at Beiersdorf includes Felicitas Hackmann (Marketing Comms, Content Creation & Project Manager), Michael Fuchs (Brand Manager 8x4) and Sara Al Madani (Brand Ambassador), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
